Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Supreme Court Upholds Lower Courts' Ruling against Pfizer's Lipitor Patent Extension

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Ending nearly two years of court battles over the patent extension of Pfizer's cholesterol drug Lipitor, South Korea's Supreme Court upheld the lower courts' rulings in favor of six local Korean pharmaceutical companies that have been selling generics of Lipitor (atorvastatin)

You may also be interested in...



MNC Products Retain Dominance In Korea As Local Generics Face Challenges

SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data

MNC Products Retain Dominance In Korea As Local Generics Face Challenges

SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data

In China, Promotion Trumps Patents

HONG KONG - In the late 1980s, Warner-Lambert researcher Bruce Roth came up with atorvastatin and changed the pharmaceutical market, and social and healthcare awareness factors in the West that made Lipitor the biggest blockbuster ever are starting to show up in China and other Asian countries. Cholesterol, heart attacks and the gamut of cardiovascular diseases are on the rise as diets grow richer, lifestyles more sedentary and smoking remains prevalent

Related Content

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel